InsidersTradesSigma
PHARMANUTRA PR PHARMANUTRA - PHN - THE BOARD OF DIRECTOR APPROVES THE 2022 SUSTAINABILITY REPORT Stock: price and directors' dealings · Italy · Consob
CONSOB:pharmanutra-pr-pharmanutra-phn-the-board-of-director-approves-the-2022-sustainabIT·ConsobMcap €861.8MHealth Care
Track the PHARMANUTRA PR PHARMANUTRA - PHN - THE BOARD OF DIRECTOR APPROVES THE 2022 SUSTAINABILITY REPORT share price and the full management transaction log of the company, a listed equity based in Italy. Shares are quoted on IT IT, under the supervision of Consob. Operating in the Health Care sector, PHARMANUTRA PR PHARMANUTRA - PHN - THE BOARD OF DIRECTOR APPROVES THE 2022 SUSTAINABILITY REPORT has logged 1 public disclosures. Market capitalisation: €861.8m. The latest transaction was filed on 17 July 2023 (Other). Among the most active insiders: Unknown. All data is accessible without an account.
1
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate PHARMANUTRA PR PHARMANUTRA - PHN - THE BOARD OF DIRECTOR APPROVES THE 2022 SUSTAINABILITY REPORT Strong Buy (bullish), based on 3 analysts. Average price target: €81.33.
Fundamental score
Ranked 8,056 of 26,212 companies
61.1
score / 100
Value37
Quality85
FCF yld1.9%
Earn yld2.3%
EV/EBITDA26.1x
ROE30%
Gross mgn77%
Net mgn15%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 17 July 2023